Skip to content

WellCareChina

Independent medical information for international patients

Menu

Disease

Ovarian cancer卵巢癌

ICD-10: C56 — Malignant neoplasm of ovary

Group: Cancer Specialty: Gynecology

Key figures

Published values only. Every tile opens the section that carries its source, its year and its caliber.

Disease details

Standard Chinese name
卵巢癌
English name
Malignant neoplasm of ovary

Values written in Chinese are quoted as published by the source.

Also known as

  • Ovarian cancer
  • Ovarian carcinoma

Treatment cost ranges

Every range below is published on one billing basis: Pre-reimbursement 医保报销前. The sources publish no post-reimbursement figure, so none is shown here.

Treatment path Cost range Price basis Data year
Surgery 手术 5000 – 5000 CNY Per-item price 项目价 2025
Surgery 手术 6000 – 6000 CNY Per-item price 项目价 2022

The bars share one scale across the rows above: each starts at that row's lower published figure and ends at its upper one. The highest upper figure on this page is 6000 CNY. Each row keeps its own data year and caliber.

2 cost ranges for this condition, each with its source on the row page.

Values written in Chinese are quoted as published by the source.

See all cost ranges →

Five-year survival

5-year survival rate 39.6%

Population
Overall (all stages combined) · Age-standardised relative survival 总体（全分期合并）· 年龄标准化相对生存率
Period
2019–2021
Publisher
National Cancer Center 国家癌症中心
Value nature
Estimated value (hybrid analysis) 估计值（混合法）
Registry scope
281 population-based cancer registries 281 个肿瘤登记处
Stage data availability
Not published

Values written in Chinese are quoted as published by the source.

See all survival rates →

How to read this figure. It is published for all stages combined, so it is an average over everyone in the national registry data rather than a prognosis for one person. For most cancers, the stage at diagnosis is the strongest single factor behind survival differences: survival is generally higher when the cancer is found at an earlier stage and lower when it is found later. Comparisons between cancers are also shaped by how early or late each one tends to be diagnosed, so a lower figure does not by itself mean worse care.

Hospitals with a published record for this condition

Selected using official public data sources

These hospitals are selected from official public data sources — the Fudan University hospital specialty reputation rankings, the national key clinical specialties list and national clinical research centres — so each line on a card can be checked against its published source. This is not a paid or promoted listing.

How these hospitals were selected

Admission. A hospital is listed for a condition when the specialty that condition is filed under carries at least one of: a place or a nomination in the Fudan University hospital specialty reputation ranking; a national key clinical specialty record at level A, B or C; or a national clinical research centre or a state key laboratory in that specialty. JCI accreditation is shown as a badge; it never decides admission and it never decides order.

Order. Step 1: a Fudan place between 1 and 10 for the specialty. Step 2: another Fudan place, or a nomination. Step 3: a level-A national key clinical specialty. Step 4: a level-B national key clinical specialty. Step 5: a national clinical research centre or a state key laboratory in the specialty, a centre before a laboratory. Step 6: a level-C national key clinical specialty, which is a record we publish without an independent official source and which is therefore listed after the others.

Ties. Within one step: the better Fudan place first, then the stronger key-specialty level (A before B before C), then the province, then the city, then the hospital name - the same province-city-name order the hospital directory uses. At most eight hospitals are listed.

When the list is short. Five hospitals or more: the first eight are listed. Three or four: all of them are listed, and a further fold adds the remaining records up to eight, each carrying its evidence level. One or two: the same, with that fold open and a line stating how many hospitals have a strong public record. None: the page states that no strong public record was found and links to the specialty directory. A place, an institution or a count is never invented to fill the list.

The Fudan rankings are the hospital specialty reputation ranking most widely recognised by Chinese clinicians, published annually by Fudan University's hospital management institute.

  1. Peking Union Medical College Hospital中国医学科学院北京协和医院

    Dongcheng District 东城区

    Fudan specialty reputation ranking 2023

    Research platform

    Also ranked: General Surgery #1, Urology #8, Otorhinolaryngology #4 in the Fudan list.

  2. Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院

    Wuhan 武汉市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Research platform

    Also ranked: General Surgery #6, Urology #5, Respiratory Medicine #8 in the Fudan list.

  3. Obstetrics and Gynecology Hospital of Fudan University复旦大学附属妇产科医院

    Shanghai 上海市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

  4. Peking University Third Hospital北京大学第三医院

    Beijing 北京市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Research platform

    Also ranked: Urology nominated, Gastroenterology nominated, Respiratory Medicine nominated in the Fudan list.

  5. Women's Hospital, School of Medicine, Zhejiang University浙江大学医学院附属妇产科医院

    Zhejiang 浙江省

    Fudan specialty reputation ranking 2023

  6. West China Second University Hospital, Sichuan University四川大学华西第二医院

    Chengdu 成都市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

  7. Qilu Hospital of Shandong University山东大学齐鲁医院

    Jinan 济南市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: Otorhinolaryngology nominated, Gastroenterology nominated in the Fudan list.

  8. Peking University People's Hospital北京大学人民医院

    Beijing 北京市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: General Surgery #10, Thoracic Surgery #7, Otorhinolaryngology nominated in the Fudan list.

Clinical trials (investigational treatments)

In addition to standard care, clinical research studies for Ovarian cancer may currently be open to participants in China. The treatments under study have not been approved by the regulator as standard therapy — they are clinical research, not routine treatment. Each record names the lead investigator and the hospital running the study. If you are interested, contact the hospital to ask about eligibility and choose whether to apply.

  1. Study FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.

    Hospital
    Peking University First Hospital
    Status
    Recruiting
    Registry
    NCT07213804

  2. Study Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicenter, Open-label, Randomized, Phase 3 Trial

    Hospital
    Women's Hospital, School of Medicine, Zhejiang University
    Status
    Recruiting
    Registry
    NCT05607329

  3. Study Fuzuloparib Plus Arsenic Trioxide in Patients With Platinum Resistance Relapsed Ovarian Cancer

    Lead investigator
    Xing Xie · profressor
    Hospital
    Women's Hospital, School of Medicine, Zhejiang University
    Status
    Recruiting
    Registry
    NCT04518501

  4. Study Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer

    Hospital
    Women's Hospital, School of Medicine, Zhejiang University
    Status
    Recruiting
    Registry
    NCT06019923

  5. Study A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112/APGOT-OV13)

    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06819007
21 more registered studies

  1. Study A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer

    Lead investigator
    Liu Yang · MD
    Hospital
    Zhejiang Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT06890858

  2. Study A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of Dual-Target CAR-NK Cells (EB-DUALNK) Following Lymphodepleting Chemotherapy in Adults With Recurrent or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

    Hospital
    Peking University Shenzhen Hospital
    Status
    Recruiting
    Registry
    NCT07589543

  3. Study Shanghai Ovarian Cancer and Family Care Project

    Hospital
    Shanghai First Maternity and Infant Hospital
    Status
    Recruiting
    Registry
    NCT06118307

  4. Study Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer: a Randomized, Controlled, Open-label Trial

    Lead investigator
    Xin Wu · Deputy Chief of Gynecologic Oncology
    Hospital
    Obstetrics and Gynecology Hospital of Fudan University
    Status
    Recruiting
    Registry
    NCT06791460

  5. Study A Phase II Study Evaluating the Efficacy and Safety of Weekly Paclitaxel or Nab-Paclitaxel Combined With Pembrolizumab and Mirabegron in Patients With Recurrent Ovarian Cancer

    Lead investigator
    Xin Wu · Director
    Hospital
    Obstetrics and Gynecology Hospital of Fudan University
    Status
    Recruiting
    Registry
    NCT07261683

  6. Study A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer

    Hospital
    The First Hospital of Jilin University
    Status
    Recruiting
    Registry
    NCT07604766

  7. Study A Single-arm, Multicenter, Phase II Study of RC48 Plus Platinum With or Without Bevacizumab in the Treatment of HER-2 Expression Platinum-Sensitive Recurrent Ovarian Cancer

    Lead investigator
    Hong Zheng · M.D.
    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06420973

  8. Study A Multicenter, Randomized, Double-blind, Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of B013 Combined With Paclitaxel in the Treatment of Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer.

    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06434610

  9. Study Nab-paclitaxel Versus Solvent-based Taxanes As First-Line Treatment for Patients With Advanced Ovarian Cancer

    Hospital
    Qilu Hospital of Shandong University
    Status
    Recruiting
    Registry
    NCT05737303

  10. Study A Randomized, Open-Label, Multi-Cohort Study of Fluzoparib Monotherapy or in Combination With Bevacizumab as Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer

    Hospital
    Qilu Hospital of Shandong University
    Status
    Recruiting
    Registry
    NCT06735326

  11. Study Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

    Lead investigator
    Jingjing Wang · associate chief physician
    Hospital
    Second Xiangya Hospital of Central South University
    Status
    Recruiting
    Registry
    NCT06660511

  12. Study A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer

    Hospital
    Peking University Third Hospital
    Status
    Recruiting
    Registry
    NCT07532434

  13. Study A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Manganese-primed Immunochemotherapy in Subjects With Advanced Ovarian Cancer

    Lead investigator
    Han weidong · Principal Investigator
    Hospital
    Chinese PLA General Hospital
    Status
    Recruiting
    Registry
    NCT07822646

  14. Study Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer：a Randomized Controlled Study

    Hospital
    Women's Hospital, School of Medicine, Zhejiang University
    Status
    Not yet recruiting
    Registry
    NCT05633199

  15. Study Stratified Evaluation and Prediction of Survival Benefit for PDS or NACT-IDS in Advanced Ovarian Cancer, A Randomized, Phase 3 Trial After the SUNNY Study

    Hospital
    Zhongshan Hospital
    Status
    Not yet recruiting
    Registry
    NCT04515602

  16. Study Efficacy of Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer: A Single-Arm, Single-Center Phase II Trial

    Hospital
    Obstetrics and Gynecology Hospital of Fudan University
    Status
    Not yet recruiting
    Registry
    NCT07673835

  17. Study An Open-label, Multicentre, Randomized, Controlled Phase III Clinical Trial Comparing HS-20089 Plus Bevacizumab Versus Investigator's Choice of Platinum-based Chemotherapy Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

    Hospital
    Anhui Provincial Hospital
    Status
    Not yet recruiting
    Registry
    NCT07821606

  18. Study Efficacy and Safety of AK104 (PD-1/CTLA-4 Bi-specific Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer: a Randomized Controlled, Single-center Clinical Study

    Hospital
    Anhui Provincial Hospital
    Status
    Not yet recruiting
    Registry
    NCT06542549

  19. Study Personalized Precision Diagnosis and Treatment of High-grade Serous Ovarian Carcinoma During the Perioperative Period Assisted by Multi-omics and Artificial Intelligence Models, and Research on the Heterogeneity of Immune Microenvironment

    Hospital
    The Affiliated Hospital of Qingdao University
    Status
    Not yet recruiting
    Registry
    NCT07721675

  20. Study Safety and Efficacy of Realgar-Indigo Naturalis Formula（RIF） Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study

    Lead investigator
    Xiaoping Li · Deputy Director, Institute of Obstetrics and Gynecology Research, Peking University People's Hospital
    Hospital
    Peking University People's Hospital
    Status
    Not yet recruiting
    Registry
    NCT07075250

  21. Study Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer

    Hospital
    Peking University Third Hospital
    Status
    Not yet recruiting
    Registry
    NCT07741630

This page only shares publicly registered study information. It does not recommend or encourage joining any study. Participation is entirely voluntary and the risks of an unapproved treatment are unknown; contact the hospital directly for eligibility and informed-consent details.

Hospitals with a national key specialty record

Show the hospital records 25 hospitals with a key-specialty record

Each row is a hospital with a national key clinical specialty record in a specialty this condition is filed under. This is a record of published listings, not a recommendation and not a ranking.

Hospital City Specialty (as published) Evidence Source
Shanghai General Hospital上海市第一人民医院 Shanghai 上海市 Gynecology 妇产临床医学中心 Level B https://www.firsthospital.cn/List/Depart/f0
Obstetrics and Gynecology Hospital of Fudan University复旦大学附属妇产科医院 Shanghai 上海市 Gynecology 妇科 Level B https://www.fckyy.org.cn/news/info/id/361.shtml
China-Japan Friendship Hospital中日友好医院 Beijing 北京市 Gynecology 妇产科 Level B https://www.zryhyy.com.cn/zryh/c100020/202309/47e8245aa93343baac89762d4e80580f.shtml
Peking University People's Hospital北京大学人民医院 Beijing 北京市 Gynecology 妇科 Level B https://www.pkuph.cn/news_details/26715.html
Peking University First Hospital北京大学第一医院 Beijing 北京市 Gynecology 妇产科（妇科、产科） Level B https://www.pkufh.com/Html/News/Articles/64494.html
Peking University Third Hospital北京大学第三医院 Beijing 北京市 Gynecology 妇产科 · Gynecology 妇科 Level B https://www.puh3.net.cn/yygk/zdxk.htm
West China Second University Hospital, Sichuan University四川大学华西第二医院 Chengdu 成都市 Gynecology 妇科 · Gynecology 妇科肿瘤全程化诊治能力提升体系及创新转化平台建设 · Gynecology 妇科（妇科恶性肿瘤多学科诊疗平台建设） Level A https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Anhui Provincial Hospital中国科学技术大学附属第一医院（安徽省立医院） Hefei 合肥市 Gynecology 妇产科 （含妇科） Level B https://www.ahslyy.com.cn/nanqu/col456/892156
The First Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院 Hefei 合肥市 Gynecology 妇产科 （含妇科） Level B https://www.ayfy.com/info/1184/27750.htm
The Second Hospital of Shandong University山东大学第二医院 Jinan 济南市 Gynecology 妇科 Level A http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
Qilu Hospital of Shandong University山东大学齐鲁医院 Jinan 济南市 Gynecology 妇科 Level A http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
Shandong Provincial Hospital山东省立医院 Jinan 济南市 Gynecology 妇科 Level A http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
Sun Yat-sen Memorial Hospital, Sun Yat-sen University中山大学孙逸仙纪念医院 Guangzhou 广州市 Gynecology 妇科 Level B https://www.gzsys.org.cn/basic/453
The First Affiliated Hospital, Sun Yat-sen University中山大学附属第一医院 Guangzhou 广州市 Gynecology 妇科 Level B https://gcp.fahsysu.org.cn/sites/1h.gcp.sysucloud1.sysu.edu.cn/files/2023-07/20230625%20中山大学附属第一医院宣传折页%20V5.0_0.pdf
Nanfang Hospital南方医科大学南方医院 Guangzhou 广州市 Gynecology 妇科 Level B https://www.nfyy.com/index.html
Guangdong Provincial People's Hospital广东省人民医院 Guangzhou 广州市 Gynecology 妇科 Level B https://www.gdghospital.org.cn/comprehensivenews/info_itemid_57420.html
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology华中科技大学同济医学院附属协和医院 Wuhan 武汉市 Gynecology 妇产科 Level B https://www.whuh.com/kxyj/xkjs/gjlczdzk/2.htm
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院 Wuhan 武汉市 Gynecology 妇科 Level B https://www.tjh.com.cn/contents/934/27291.html
Central Hospital of Wuhan武汉市中心医院 Wuhan 武汉市 Gynecology 妇产科 Level B https://zxhospital.com/gcp/info/1031/1548.htm
Third Xiangya Hospital中南大学湘雅三医院 Changsha 长沙市 Gynecology 妇科 Level B https://www.xy3yy.com/ksjj/184173.html
Shengjing Hospital中国医科大学附属盛京医院 Shenyang 沈阳市 Gynecology 妇科 Level B https://www.sj-hospital.cn/article/80.html
Liaoning Cancer Hospital辽宁省肿瘤医院 Shenyang 沈阳市 Gynecology 妇科 Level B https://www.lnchi.org.cn/ch/hospital/biref/index.html
Chongqing University Cancer Hospital重庆大学附属肿瘤医院 Chongqing 重庆市 Gynecology 妇科 Level A https://wsjkw.cq.gov.cn/zwgk_242/fdzdgknr/tzgg/gzgs/202405/t20240515_13209571.html
The First Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院 Xi'an 西安市 Gynecology 妇科 Level B http://www.dyyy.xjtu.edu.cn/info/41461/122341.htm
The Second Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院 Xi'an 西安市 Gynecology 妇科 Level B http://2yuan.xjtu.edu.cn/defsyy/xwzx1/yyyw_/4.htm

25 hospitals with a matching national key specialty record.

Values written in Chinese are quoted as published by the source.

Questions about this condition

We cannot give medical advice, but we can answer questions about this page and about arranging treatment in China.

Ask us about this condition

ICD codes

Show the code table 6 ICD codes
Version Code Name in that version
ICD-10-WHO C56 Malignant neoplasm of ovary
ICD-10-WHO C57.0 Fallopian tube
ICD-10-WHO C57.1 Broad ligament
ICD-10-WHO C57.2 Round ligament
ICD-10-WHO C57.3 Parametrium
ICD-10-WHO C57.4 Uterine adnexa, unspecified

Rows are the WHO ICD-10 entries for this condition, quoted as published.

Source & evidence

Source URL
https://www3.ha.org.hk/cancereg/tc/icd10.html
Source scheme
https
Source type
Third-party compilation
Evidence level
A - said by a provincial health commission or university
Retrieved on
2026-10-01